UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Dec

14 UCB’s Health Equity First Approach to Addressing Population Health Challenges

Read More Share:

Dec

13 Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Read More Share:

Dec

09 UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Read More Share:

Dec

07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:

Dec

01 UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Read More Share:

Nov

23 Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Read More Share:

Nov

22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:

Nov

21 Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

Read More Share:

Nov

17 Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Read More Share:

Categories

Archives

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

14

UCB’s Health Equity First Approach to Addressing Population Health Challenges

Dec

13

Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Dec

09

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Dec

01

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Nov

23

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

21

Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

14

UCB’s Health Equity First Approach to Addressing Population Health Challenges

Dec

13

Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Dec

09

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Dec

01

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Nov

23

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

21

Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact